Underweight MO: Trim 15-25% at $68.50-$69.00, preserve 75-80% for dividend carry, hard stop $64.50
Underweight rating is calibrated by the binding reflection ledger—the contested-pivot Hold framework has empirically bled alpha across six consecutive iterations (9/17, 9/18, 9/21, 9/23, 9/24, 9/28), with the 9/28 binding reflection explicitly prohibiting another passive Hold at the same pivot. The trim magnitude sits between passive Hold and full Sell because while the contested-pivot alpha decay is binding, the structural floor remains documented (1.30x FCF coverage, 200 SMA rising from $60.97 to $65.24, dividend raised to $1.11, 0.49 beta with 97% no-cut Polymarket probability). The 15-25% trim preserves dividend carry while acknowledging the 2-to-1 risk-reward against the passive position (from $68.72: $3.48 downside to 200 SMA stop vs $1.68 upside to upper Bollinger at $70.40). Re-evaluate at NJOY PMTA outcome and Q3 2026 earnings.
| Position | Action |
|---|---|
| Current levels ($68.50-$69.00) | Trim 15-25% (first tranche 10-15%) |
| Confirmed retest of $70.40 with volume rejection >12M | Trim additional 5-10% (second tranche) |
| Confirmed close >$70.65 on volume >12M with RSI >55 | Add up to 25% of residual position |
| MO closes below prior 10-day low against SPY | Trigger additional 10% trim (MO/SPY relative-strength invalidator) |
| Daily close below $64.50 | Hard stop and exit remaining position |
Altria is a defensive yield name with exceptional cash generation (76.4% operating margins, $9.07B annual FCF), 57 years of dividend growth, and a smoke-free portfolio hitting critical mass — all trading at a 25%+ discount to consumer staples peers.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $68.86 | neutral |
| 50 SMA | $67.90 | bullish |
| 200 SMA | $65.24 | bullish |
| RSI (14) | 52.32 | neutral |
| MACD | 0.39 | neutral |
| MACD Signal | 0.41 | neutral |
| MACD Histogram | -0.02 | bearish |
| ATR (14) | $1.30 | neutral |
| Bollinger Middle Band (20 SMA) | $68.65 | neutral |
| Bollinger Upper Band | $70.40 | bearish |
| Bollinger Lower Band |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: MO closes below prior 10-day low against SPY
Then: Trigger additional 10% trim
↩ rebuts: “Bear thesis that MO is only a cigarette company playing defense”
EV: +5.5% to $73+ (re-test of July highs)
MO is a structural decline story wearing a yield costume — the 100% payout ratio dividend is a trap, not a fortress.
EV: -$3.48 to -$5.48 (price targets: $66.90 to $65.24 from $68.72 entry) · concedes: 57 years of consecutive dividend increases is genuinely impressive; The current 6.46% yield is real and has been sustained; Marlboro maintains genuine pricing power in the near term; Some FCF coverage (1.30×) exists above dividend, though thin
→ vs neutral: The 'two failed $70.40 breakouts' represent misinterpreted technicals; compression regimes with ATR at $1.30, BBW at $3.50, and MACD at negative 0.02 resolve violently upward, not downward
→ vs conservative: The 100.1% GAAP payout ratio is misleading; real FCF coverage is 1.30x with $9B FCF against $6.96B dividend, and anchoring on non-cash accounting metrics while ignoring cash generation is 'borderline malpractice'
→ vs neutral: FDA catalyst is 'criminally understated' as 'moderate positive'; Trump admin regulatory restructuring for smoke-free products combined with 120,000-store distribution is a 'structural rerating opportunity'
→ vs conservative: The Polymarket data and actual rate trajectory make a 'Treasury yield rally' compressing MO's premium a zero-probability scenario through year-end
| $66.90 |
| bullish |
Support: 66.9 · 67.9 · 65.24 | Resistance: 70.4 · 70.1
MO exhibits a neutral-to-mildly-bullish technical setup with price ($68.72) above both the 50 SMA ($67.90, +1.20%) and 200 SMA ($65.24, +5.34%), confirming an intact uptrend. The 10 EMA ($68.86) sitting nearly equal to price signals short-term indecision. RSI at 52.32 is neutral, while MACD shows a marginal bearish crossover (0.39 vs 0.41 signal line) with histogram at -0.02. ATR has compressed from $1.74 to $1.30, with Bollinger Bands tightening between $66.90 and $70.40. The stock has ranged from $64.17 (8/18 low) to $70.10 (9/16 high) over 30 days, forming a higher-low pattern since August. The analyst recommends HOLD for existing holders and suggests tactical entries on pullback to $67.90-$66.90 or breakout above $70.40.
Market Cap
$112.4 B
P/E (TTM)
14.18×
Forward P/E
11.48×
PEG Ratio
2.63
Dividend Yield
6.46%
Beta
0.49
EPS (TTM)
$4.75
Forward EPS
$5.86
52-Week Range
$54.70 – $77.06
Net Revenue (FY25)
$20,139 M
Net Revenue (FY24)
$20,444 M
Net Revenue (FY23)
$20,502 M
Net Revenue (FY22)
$20,688 M
Gross Profit (FY25)
$14,542 M
Gross Profit (TTM)
$17.8 B
Operating Income (FY25)
$12,035 M
Operating Income (FY24)
$11,641 M
Operating Margin
76.4%
Net Income (FY25)
$6,947 M
Net Income (FY24)
$11,264 M
Net Income (TTM)
$7.95 B
Diluted EPS (FY25)
$4.12
Diluted EPS (FY24)
$6.54
Diluted EPS (Q2'26)
$1.37
Diluted EPS (Q1'26)
$1.30
Diluted EPS (Q4'25)
$0.66
Diluted EPS (Q3'25)
$1.41
Diluted EPS (Q2'25)
$1.41
Total Debt
$24.6 B
Net Debt
$22.2 B
Cash & Equivalents
$2.4 B
Stockholders' Equity
($2.7 B)
Treasury Stock
$43.5 B
Current Ratio
0.52
Working Capital
($3,748 M)
Goodwill & Intangibles
$17.6 B
ABI Investment (Book Value)
$8.9 B
Operating Cash Flow (FY25)
$9,290 M
Free Cash Flow (FY25)
$9,074 M
Free Cash Flow (TTM)
$9.03 B
CapEx (FY25)
$216 M
Dividends Paid (FY25)
$6,960 M
Buybacks (FY25)
$1,000 M
FCF/Dividend Coverage
1.30×
FCF Conversion
97.7%
EBITDA (TTM)
$15.8 B
Profit Margin
39.0%
ROA
29.5%
Normalized Quarterly EPS
~$1.35–$1.40
Strengths
Concerns
Altria Group is a defensive, income-oriented tobacco equity with a 6.46% dividend yield (among the highest in the S&P 500) backed by $9B+ in annual free cash flow and 1.30× dividend coverage. FY2025 net income declined 38% to $6.95B due to $2.14B in impairment and restructuring charges, but Q1-Q2 2026 quarterly EPS of $1.30-$1.37 confirms the underlying earnings power remains intact at a ~$2.6B quarterly run-rate. The stock trades at a forward P/E of 11.48× with low beta (0.49), offering a margin of safety relative to consumer staples peers, though secular cigarette volume decline, FDA/regulatory risks, and litigation overhang warrant a HOLD recommendation with accumulation preferred on pullbacks toward the 200-day moving average (~$67.24).
Macro: Rising long-end Treasury yields (30-year at highest since 2002, mortgage rates near 7.58%) with the Fed firmly on hold (Polymarket prices 97% odds of zero 2026 rate cuts); recession odds at only 8% by end-2026 supporting a soft-landing base case; broader equity markets wavering with monthly losses for DOW and S&P driving rotation into defensives; Moody's Zandi notes higher rates are already damaging the economy, posing mild headwind for consumer pricing power.